Harbin Pharmaceutical Group Co., Ltd. Sustainability Profile
Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical industry, headquartered in Harbin, China. Established in 1997, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include prescription medications, over-the-counter products, and health supplements, distinguished by their efficacy and adherence to stringent safety standards. Recognised for its robust research and development capabilities, Harbin Pharmaceutical Group has achieved notable milestones, positioning itself as a trusted name in healthcare. Its dedication to advancing medical solutions continues to enhance its reputation within the global pharmaceutical landscape.
DitchCarbon Score
How does Harbin Pharmaceutical Group Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harbin Pharmaceutical Group Co., Ltd.'s score of 45 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harbin Pharmaceutical Group Co., Ltd.'s reported carbon emissions
In 2023, Harbin Pharmaceutical Group Co., Ltd. reported total carbon emissions of approximately 4,493,880 kg CO2e for Scope 1, 71,231,080 kg CO2e for Scope 2 (market-based), and a significant 3,563,551,150 kg CO2e for Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, covering all three scopes. Comparatively, in 2022, the company recorded Scope 1 emissions of about 3,921,950 kg CO2e, Scope 2 emissions of 64,116,060 kg CO2e (location-based), and Scope 3 emissions of approximately 2,453,614,300 kg CO2e. The increase in emissions across these scopes highlights the ongoing challenges in managing carbon outputs. Harbin Pharmaceutical has set ambitious climate commitments, aiming for an 88% reduction in Scope 1 emissions by 2045, relative to 2022 levels. Additionally, the company targets a 36% reduction in Scope 1 emissions by 2030. They also strive to peak emissions across all scopes by 2030, indicating a proactive stance towards climate action. These commitments are part of a broader strategy to enhance sustainability and reduce the environmental impact of their operations, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,217,510 | 0,000,000 | 0,000,000 |
| Scope 2 | 37,994,740 | 00,000,000 | 00,000,000 |
| Scope 3 | 126,213,440 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Harbin Pharmaceutical Group Co., Ltd.'s Industry?
How Carbon Intensive is Harbin Pharmaceutical Group Co., Ltd.'s Location?
Harbin Pharmaceutical Group Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Harbin Pharmaceutical Group Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
